与其他肿瘤浸润性T细胞相比,CD103+ TRM表达多种免疫检查点受体,如程序性死亡受体1(programmed cell death 1, PD-1)、淋巴细胞活化基因-3(lymphocyte activation gene-3, LAG-3)、T细胞免疫球蛋白黏蛋白分子-3(T cell immunoglobulin and mucin-containing molecule-3, TIM-3)和细胞毒性T淋巴细胞相关抗原-4(cytotoxic T lymphocyte-associated antigen-4, CTLA-4)[19, 35, 52, 60-64],而NSCLC来源的TRM不表达CTLA-4[19],与其维持自身抗原耐受的能力相关[40, 65]。. Here, CTLA4 is linked to non-small cell lung carcinoma.